Hypermarcas gains strength in the pharmaceutical industry

Created in 2001 to be a consumer, the giant Hypermarcas, businessman Ganesan John ADAS Filho, better known as junior, began to change course in 2009, when the company started to make heavy bets on the pharmaceutical segment, which recorded double-digit growth up until last year and today accounts for 55% of the revenue of the group. Hypermarcas a datewith an aggressive move acquisition, Hypermarcas began to bother the competitors, especially in the segment of generics. Today, the pharmaceutical division is already the second largest in the Brazilian market, behind the EMS. In August, its market share was at 12.81%, almost against the leader who ended the same month with 13.17 percent slice, according to the consulting firm IMS Health, specializing in the pharmaceutical industry. The company took in 2013 the Deputy leadership by French Sanofi, owner of the Medley, which has today 8.69% of the Brazilian market. The company wants to market leadership. To get there, some factors weigh in his favor, according to analyst Ricardo Boiati, Bradesco BBI. One of them is your cost of production of generics, which, on the basis of a modern industrial park, gets to be 30% lower than that of major competitors. In addition, Boiati claims that the company made investments in marketing in the Neo chemistry, trying to differentiate the lab of generic medicines, which are considered a sort of commodity in the industry
"The Group wants to focus on drugs and be a global company such as Bayer and Sanofi itself, for example, that have a broad portfolio of medicines and non-prescription products," said a market source.
According to the retail analyst Luiz basket, Votorantim Corretora, the prospects for the sector of medicines are good in the long run, because the trend is ageing of the population. Thinking about it, want to gain muscles and Hypermarcas expand their domains, in a new wave of consolidation in the future. Came to probe the Aché, national laboratory of families Depieri, Siaulys and Dellape Baptista, who decided to put the business on the market for nearly three years. Aché also negotiated with multinationals, but the process didn't go. Sources say Hypermarcas would still have interest in the Aché
Aggression. The construction of the pharmaceutical Empire Hypermarcas did, as occurred in consumer goods, for acquisitions. Between 2009 and 2010, the company snatched the Neo chemistry, of Goiás, and the Mantegazza family Mantecorp, taking international competitors of weight of the race.
These two businesses, in fact, helped inflate the price of pharmaceutical assets in the market. With the growth of the Division, the company gained the attention of financial markets
Even though the strategy of separating the consumer goods business, operating well by the market, doesn't succeed, Hypermarcas as a whole is considered to be a good asset. On Tuesday, the credit rating agency Fitch maintained the company's note "BB +", with positive Outlook. Several banks recommend buying action. "The pharmaceutical industry is doing well and in consumption, the company has good performance," says Caio Moreira, an analyst at banco Fator.
To remember: group became more lean and mean
Hypermarcas began to put into practice in 2011, ten years after its inception, a broad restructuring of its business plan. Known by its aggressive move of acquisitions, the company had to review its strategy, which included the sale of various assets. The market began to question the lack of focus of the group, which had a range of businesses, from health and beauty to cleaning and food. In 2011, the company sold its food assets and cleaning, just the ones that gave rise to the business. The group got rid of a package of important brands such as Communitydns, Perfex, Etti and Salsaretti, which totaled r $ 445 million
In addition, Hypermarcas also concentrated most of its factories in Goiás. With investments of r $ 500 million, built on complex industrial and State distribution centers to unify the production of its two businesses: drugs and consumption. In Annapolis, the seat of the Neo has the largest Chemical manufacturing capacity of remedies of Latin America-the bunker of medicines ", as the structure is known internally, allowed the deactivation of factories in the industry that were once spread over several States.
The Division of consumer goods is in Goiania and concentrates production units named "project Matrix". You're just out of the Matrix Division of disposable diapers, which is in Aparecida de Goiânia and is on sale.